Regulations.gov document
Vanda Pharmaceuticals Inc.’s Submission in Support of Summary Judgment to the Applicant or…
Other · FDA-2022-N-2390 · posted Mar 4, 2025
Key facts
| Document ID | FDA-2022-N-2390-0132 |
|---|---|
| Title | Vanda Pharmaceuticals Inc.’s Submission in Support of Summary Judgment to the Applicant or a Hearing on Approvability of Tasimelteon to Treat Insomnia Associated with Difficulties with Sleep Initiation |
| Document type | Other |
| Subtype | Brief |
| Agency | FDA |
| Docket | FDA-2022-N-2390 |
| Posted | Mar 4, 2025 |
| Comment period opens | Mar 4, 2025 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: